Information  X 
Enter a valid email address

EPIC/TIDM matching '0QLR'

Date
Time Source
Company
Announcement
09 Dec 2019 7:45 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
06 Dec 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
05 Dec 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day
  6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis tender offer for The Medicines Company commences
24 Nov 2019 8:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
17 Nov 2019 3:45 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
15 Nov 2019 8:06 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
  11:27 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
12 Nov 2019 6:25 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment
  6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis
11 Nov 2019 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market
05 Nov 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)
01 Nov 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
30 Oct 2019 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces AVXS-101 intrathecal study update
24 Oct 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis
22 Oct 2019 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
08 Oct 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
  6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
02 Oct 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
01 Oct 2019 3:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
30 Sep 2019 6:20 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
  6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
29 Sep 2019 3:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
  3:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
19 Sep 2019 8:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
18 Sep 2019 1:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin
17 Sep 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
13 Sep 2019 1:15 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
03 Sep 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
02 Sep 2019 7:30 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
01 Sep 2019 1:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint
30 Aug 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
09 Aug 2019 8:46 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case
06 Aug 2019 11:08 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
31 Jul 2019 3:05 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials
29 Jul 2019 6:00 am GNW Factsheet Novartis International AG (0QLR) Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
26 Jul 2019 1:06 pm GNW Factsheet Novartis International AG (0QLR) Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness
22 Jul 2019 6:15 am GNW Factsheet Novartis International AG (0QLR) Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
18 Jul 2019 6:00 am GNW Factsheet Novartis International AG (0QLR) Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
16 Jul 2019 6:15 am GNW Factsheet Novartis International AG (0QLR) FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
11 Jul 2019 9:30 pm GNW Factsheet Novartis International AG (0QLR) Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention
01 Jul 2019 4:30 pm GNW Factsheet Novartis International AG (0QLR) Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
14 Jun 2019 7:30 am GNW Factsheet Novartis International AG (0QLR) Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)
12 Jun 2019 6:20 am GNW Factsheet Novartis International AG (0QLR) Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
  6:15 am GNW Factsheet Novartis International AG (0QLR) Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis
07 Jun 2019 6:00 am GNW Factsheet Novartis International AG (0QLR) Novartis announces new leader of Pharmaceuticals Business Unit
06 Jun 2019 6:15 am GNW Factsheet Novartis International AG (0QLR) Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible
04 Jun 2019 6:00 pm GNW Factsheet Novartis International AG (0QLR) Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
03 Jun 2019 6:15 am GNW Factsheet Novartis International AG (0QLR) Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
  6:00 am GNW Factsheet Novartis International AG (0QLR) Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
01 Jun 2019 12:30 pm GNW Factsheet Novartis International AG (0QLR) Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
30 May 2019 6:15 am GNW Factsheet Novartis International AG (0QLR) Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
24 May 2019 9:12 pm GNW Factsheet Novartis International AG (0QLR) FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
  5:42 pm GNW Factsheet Novartis International AG (0QLR) AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
  5:30 pm GNW Factsheet Novartis International AG (0QLR) AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
23 May 2019 6:15 am GNW Factsheet Novartis International AG (0QLR) Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event
22 May 2019 6:15 am GNW Factsheet Novartis International AG (0QLR) Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
16 May 2019 2:00 pm GNW Factsheet Novartis International AG (0QLR) Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
08 May 2019 11:20 pm GNW Factsheet Novartis International AG (0QLR) Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
  6:15 am GNW Factsheet Novartis International AG (0QLR) Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t